Cargando…
The Anti-diabetic Drug Gliquidone Modulates Lipopolysaccharide-Mediated Microglial Neuroinflammatory Responses by Inhibiting the NLRP3 Inflammasome
The sulfonylurea drug gliquidone is FDA approved for the treatment of type 2 diabetes. Binding of gliquidone to ATP-sensitive potassium channels (SUR1, Kir6 subunit) in pancreatic β-cells increases insulin release to regulate blood glucose levels. Diabetes has been associated with increased levels o...
Autores principales: | Kim, Jieun, Park, Jin-Hee, Shah, Keshvi, Mitchell, Scott John, Cho, Kwangwook, Hoe, Hyang-Sook |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8587901/ https://www.ncbi.nlm.nih.gov/pubmed/34776934 http://dx.doi.org/10.3389/fnagi.2021.754123 |
Ejemplares similares
-
Gliquidone
por: Gelbrich, Thomas, et al.
Publicado: (2011) -
Interaction between autophagy and the NLRP3 inflammasome in Alzheimer’s and Parkinson’s disease
por: Lu, Ranran, et al.
Publicado: (2022) -
Salidroside Ameliorates Alzheimer's Disease by Targeting NLRP3 Inflammasome-Mediated Pyroptosis
por: Cai, Yawen, et al.
Publicado: (2022) -
The NLRP3 Inflammasome Pathway: A Review of Mechanisms and Inhibitors for the Treatment of Inflammatory Diseases
por: Blevins, Hallie M., et al.
Publicado: (2022) -
Editorial: The NLRP3 inflammasome-mediated neuroinflammation and its related mitochondrial impairment in neurodegeneration
por: Deng, Chao, et al.
Publicado: (2023)